Search

for
Search:

GlossaryDabrafenib

medication targeting BRAF V600E mutation in melanoma

Dabrafenib is a medication used to treat certain types of cancer, specifically melanoma with a BRAF V600E mutation. It works by inhibiting the activity of the BRAF protein, which is involved in cell growth and division, thereby slowing down or stopping the growth of cancer cells.

Related Terms

Learn

0 / 0 results

— no results

Research

5 / 58 results

research BRAF Inhibitor Dabrafenib in Patients with Metastatic BRAF-Mutant Thyroid Cancer

188 citations, October 2014 in “Thyroid”

Dabrafenib was effective and well tolerated in treating thyroid cancer with a specific mutation.

research Cutaneous Manifestations of Dabrafenib: A Selective Inhibitor of Mutant BRAF in Patients with Metastatic Melanoma

173 citations, July 2012 in “British Journal of Dermatology”

Dabrafenib can cause skin growths and sometimes low-grade skin cancer.

research Cutaneous Adverse Effects of BRAF Inhibitors in Metastatic Malignant Melanoma: A Prospective Study in 20 Patients

31 citations, March 2014 in “Journal of the European Academy of Dermatology and Venereology”

BRAF inhibitors for melanoma often cause skin side effects, but they can be managed with proper care.

research Cutaneous Toxicities of New Treatments for Melanoma

25 citations, May 2018 in “Clinical & Translational Oncology”

New melanoma treatments can cause skin side effects, including skin cancer and rashes, but combining treatments may reduce these risks.

research Prospective Case Series of Cutaneous Adverse Effects Associated With Dabrafenib and Trametinib

10 citations, September 2016 in “Journal of cutaneous medicine and surgery”

Patients on dabrafenib and trametinib for melanoma often experience skin side effects.

View more "dabrafenib" in research →

Community Join

0 / 0 results

— no results